Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Current Liabilities (2021 - 2025)

ARS Pharmaceuticals' Total Current Liabilities history spans 5 years, with the latest figure at $39.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 67.0% year-over-year to $39.1 million; the TTM value through Dec 2025 reached $39.1 million, up 67.0%, while the annual FY2025 figure was $39.1 million, 67.0% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $39.1 million at ARS Pharmaceuticals, down from $50.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $50.9 million in Q3 2025 and bottomed at $2.4 million in Q4 2023.
  • The 5-year median for Total Current Liabilities is $11.4 million (2021), against an average of $16.7 million.
  • The largest annual shift saw Total Current Liabilities plummeted 74.0% in 2022 before it soared 880.34% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $8.2 million in 2021, then plummeted by 33.5% to $5.4 million in 2022, then plummeted by 56.08% to $2.4 million in 2023, then skyrocketed by 880.34% to $23.4 million in 2024, then surged by 67.0% to $39.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Total Current Liabilities are $39.1 million (Q4 2025), $50.9 million (Q3 2025), and $45.6 million (Q2 2025).